TY - JOUR

T1 - Parameters Optimization of Edoxaban Extraction from Dried Plasma Spots

AU - Zakabluk, G. A.

AU - Koval, V. V.

AU - Chernonosov, A. A.

PY - 2020

Y1 - 2020

N2 - Aims: Edoxaban is a direct-acting oral anticoagulant, being a highly selective, direct and reversible factor Xa inhibitor. Edoxaban is used to treat and prevent blood clots such as deep vein thrombosis and pulmonary embolism. The dried spot technic, including dried blood spots and dried plasma spots, is used in many fields, from newborn screening to monitoring of therapeutic drugs in toxicology. In this case, equipment with a highly sensitive detector, such as a mass spectrometer, is required, as well as conditions for a high degree of drug recovery from the dried spot. In this work, the extraction of edoxaban from dried plasma spots (DPS) was studied to determine the optimal parameters of the extraction method.Study Design: Analytical experimental study. Short Research Articles.Place and Duration of Study: Core Facility of Mass Spectrometric Analysis, Institute of Chemical Biology and Fundamental Medicine SB RAS, between August and October 2020Methodology: The organic extraction method was selected for evaluation as the most suitable for LC-MS analysis. Several parameters were investigated to find the best combination for extracting edoxaban from DPS for further LC-MS analysis: percent organic solvent, presence or absence of 0.1% formic acid (FA), extraction time, volume, and temperature.Results: The results showed that the extraction was influenced by the composition and volume of the solvent, but not temperature and time. Pure acetonitrile is the worst solvent for extracting edoxaban from DPS. The most optimal parameters are MeOH: 0.1% FA in H2O (70:30, v:v) solvent with an extraction temperature of 40 degrees C, an extraction time of 15 minutes and a solvent volume of 50 mu l.Conclusion: Several solvents suitable for LC-MS analysis can be used to recover edoxaban from DPS.

AB - Aims: Edoxaban is a direct-acting oral anticoagulant, being a highly selective, direct and reversible factor Xa inhibitor. Edoxaban is used to treat and prevent blood clots such as deep vein thrombosis and pulmonary embolism. The dried spot technic, including dried blood spots and dried plasma spots, is used in many fields, from newborn screening to monitoring of therapeutic drugs in toxicology. In this case, equipment with a highly sensitive detector, such as a mass spectrometer, is required, as well as conditions for a high degree of drug recovery from the dried spot. In this work, the extraction of edoxaban from dried plasma spots (DPS) was studied to determine the optimal parameters of the extraction method.Study Design: Analytical experimental study. Short Research Articles.Place and Duration of Study: Core Facility of Mass Spectrometric Analysis, Institute of Chemical Biology and Fundamental Medicine SB RAS, between August and October 2020Methodology: The organic extraction method was selected for evaluation as the most suitable for LC-MS analysis. Several parameters were investigated to find the best combination for extracting edoxaban from DPS for further LC-MS analysis: percent organic solvent, presence or absence of 0.1% formic acid (FA), extraction time, volume, and temperature.Results: The results showed that the extraction was influenced by the composition and volume of the solvent, but not temperature and time. Pure acetonitrile is the worst solvent for extracting edoxaban from DPS. The most optimal parameters are MeOH: 0.1% FA in H2O (70:30, v:v) solvent with an extraction temperature of 40 degrees C, an extraction time of 15 minutes and a solvent volume of 50 mu l.Conclusion: Several solvents suitable for LC-MS analysis can be used to recover edoxaban from DPS.

KW - Dried plasma spot

KW - DPS

KW - DBS

KW - edoxaban

KW - LC-MS/MS

KW - extraction

KW - ORAL ANTICOAGULANTS

KW - BLOOD

U2 - 10.9734/JPRI/2020/v32i3230941

DO - 10.9734/JPRI/2020/v32i3230941

M3 - Article

VL - 32

SP - 119

EP - 127

JO - Journal of pharmaceutical research international

JF - Journal of pharmaceutical research international

SN - 2456-9119

IS - 32

M1 - 62931

ER -